Embecta Corp. (FRA:JX7)
Germany · Delayed Price · Currency is EUR | Market Cap | 339.51M -52.7% |
| Revenue (ttm) | 891.67M -7.6% |
| Net Income | 76.59M +4.7% |
| EPS | 1.31 +3.4% |
| Shares Out | n/a |
| PE Ratio | 4.52 |
| Forward PE | 4.21 |
| Dividend | 0.27 (4.61%) |
| Ex-Dividend Date | Aug 27, 2026 |
| Volume | 250 |
| Open | 6.02 |
| Previous Close | 5.77 |
| Day's Range | 5.93 - 6.02 |
| 52-Week Range | 2.44 - 12.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |
About Embecta
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company’s products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey. [Read more]
Financial Performance
In fiscal year 2025, Embecta's revenue was $1.08 billion, a decrease of -3.80% compared to the previous year's $1.12 billion. Earnings were $95.40 million, an increase of 21.84%.
Financial numbers in USD Financial StatementsNews
embecta to Participate in Investor Events
In September, embecta will participate in the Wells Fargo 2026 Healthcare Conference and the J.P. Morgan 4th Annual Nashville Healthcare Conference 2026.
EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop
A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insuli...
Kaplan Fox Reminds Embecta Corp. (NASDAQ: EMBC) Investors with Significant Losses to Seek a Leadership Role Before Deadline on August 17, 2026
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) on behalf...
Kaplan Fox Notifies Embecta Corp. (EMBC) Investors of an Upcoming Lead Plaintiff Deadline on August 17, 2026
New York, New York--(Newsfile Corp. - August 12, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EM...
EMBC Investor Announcement: Embecta Sued on behalf of Investors to Recover Losses after Insulin Pen Issues Lead to 57% Stock Drop
A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insuli...
Embecta Earnings Call Transcript: Q3 2026
Q3 2026 saw sequential revenue and profit improvement, driven by international growth and the Owen Mumford acquisition, despite year-over-year declines. Guidance for FY2026 was reaffirmed or raised, with a focus on cost controls, debt reduction, and expanded product offerings.
Embecta Earnings release: Q3 2026
Embecta released its Q3 2026 earnings on August 7, 2026, summarizing the period's financial results.
Embecta Slides: Q3 2026
Embecta has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 7, 2026.
Embecta Quarterly report: Q3 2026
Embecta has published its Q3 2026 quarterly earnings report on August 7, 2026.
Embecta reports Q3 adjusted EPS 56c vs. $1.12 last year
Reports Q3 revenue $271.7M, consensus $254.54M. “Our third quarter results improved significantly on a sequential basis, with revenue increasing approximately $50 million, GAAP operating income increa...
Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results
PARSIPPANY, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical...
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 for each issued and outstanding s...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 17, 2026 in Embecta Corp. Lawsuit - EMBC
Key Dates and Disclosure Events Embecta Shareholders Need to Know: From "Incredibly Resolute" Pen Needle Claims to a 57.8% Stock Collapse NEW YORK, Aug. 6, 2026 /PRNewswire/ -- November 25, 2025. Janu...
Kaplan Fox Urges Investors of Embecta Corp. (EMBC) with Significant Losses to Seek a Leadership Role Before August 17, 2026
New York, New York--(Newsfile Corp. - July 27, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC...
EMBC Stock Drop: If You Incurred Significant Losses in Embecta Corp., Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Embecta Corp. (NASDAQ: EMBC) ...
$EMBC Fraud Notification: Embecta Sued for Fraud Over Misrepresentations about its Insulin Pen Issues – Investors Notified to Contact BFA Law
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain...
embecta to Report Fiscal Third Quarter Financial Results
PARSIPPANY, N.J., July 23, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical...
Kaplan Fox Reminds Embecta Corp. (EMBC) Investors Seeking Recovery of the Lead Plaintiff Deadline on August 17, 2026
New York, New York--(Newsfile Corp. - July 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC...
$EMBC Fraud Notification: Embecta Sued for Securities Fraud After Insulin Pen Issues Spark a 57% Stock Drop – Investors Notified to Contact BFA Law by August 17
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain...
EMBC Stockholders Have Rights – If You Lost Money Investing in Embecta Corp. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Embecta Corp. (NASDAQ: EMBC) ...
EMBECTA CORP. (EMBC) INVESTOR ALERT Investors With Large Losses in Embecta Corp. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
embecta appoints Nimish Muzumdar as SVP and President, North America
PARSIPPANY, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical...
Embecta price target lowered to $3 from $11 at BofA
BofA analyst Travis Steed lowered the firm’s price target on Embecta (EMBC) to $3 from $11 and keeps an Underperform rating on the shares. After having hosted 34 medtech companies…
embecta Completes Acquisition of Owen Mumford Holdings Limited
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has completed its previously announced...
Embecta Transcript: Bank of America Global Healthcare Conference 2026
U.S. instability from share loss and market softness prompted a guidance cut and accelerated diversification efforts. New products, B2B partnerships, and the Owen Mumford acquisition are expected to drive growth and broaden the portfolio. Free cash flow remains strong, supporting buybacks and debt reduction.